Health
Roche Falls as Side Effects Data for Obesity Drug Raises Concern
- Poster shows early-stage data for experimental CT-388
- Roche will present data at this week’s EASD annual meeting
Roche headquarters in Basel, Switzerland.
Photographer: Stefan Wermuth/BloombergThis article is for subscribers only.
Shares of Roche Holding AG fell after a poster highlighted side effects in an early-stage study of the Swiss pharmaceutical company’s experimental obesity medicine.
The poster, released as part of this week’s European Association for the Study of Diabetes annual meeting, showed side effects including nausea, vomiting and diarrhea for Roche’s injectable drug, CT-388. The stock fell as much as 4.5% in Zurich on Monday.